Evidence map›Paper›PMID 38457512›Full record

ArticleScience advances2024

Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes.

Jikui Shen, Raquel Lima E Silva, Mingliang Zhang, Kathryn M Luly, Sean F Hackett, Stephany Y Tzeng, Shirley M Lowmaster, Sydney R Shannon, David R Wilson, Jordan J Green and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Surgical Approaches to Retinal Gene Therapy: 2025 Update.Bioengineering (Basel, Switzerland) · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jikui ShenDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-5262-5606
Raquel Lima E SilvaDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-4325-5754
Mingliang ZhangDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2285-3592
Kathryn M LulyDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0001-9020-9155
Sean F HackettDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Stephany Y TzengDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-7561-482X
Shirley M LowmasterDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0009-0005-3631-257X
Sydney R ShannonDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David R WilsonDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-8708-4248
Jordan J GreenDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-4176-3808
Peter A CampochiaroDepartment of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-2531-8229
Johns Hopkins University · US

Funding

Translational Research for Retinal Degeneration TherapiesR01EY017549 · NEI · UNIVERSITY OF PENNSYLVANIA · PI BELTRAN, WILLIAM A. · 2007 to 2024
$14.1M
Suprachoroidal nonviral gene transfer of engineered VEGF antagonistsR01EY031097 · NEI · JOHNS HOPKINS UNIVERSITY · PI CAMPOCHIARO, PETER A, GREEN, JORDAN · 2020 to 2023
$2.4M
Tri-Signal Artificial Antigen Presenting Cells for Cancer ImmunotherapyF31CA284859 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHANNON, SYDNEY ROSE · 2023 to 2025
$129k
NCI NIH HHS F31 CA284859NEI NIH HHS R01 EY017549NEI NIH HHS R01 EY031097
6 · The paper itself

Abstract

Suprachoroidal nonviral gene therapy with biodegradable poly(β-amino ester) nanoparticles (NPs) provides widespread expression in photoreceptors and retinal pigmented epithelial (RPE) cells and therapeutic benefits in rodents. Here, we show in a human-sized minipig eye that suprachoroidal injection of 50 μl of NPs containing 19.2 μg of GFP expression plasmid caused GFP expression in photoreceptors and RPE throughout the entire eye with no toxicity. Two weeks after injection of 50, 100, or 200 μl, there was considerable within-eye and between-eye variability in expression that was reduced 3 months after injection of 200 μl and markedly reduced after three suprachoroidal injections at different locations around the eye. Reduction of bacterial

Indexed as

NanoparticlesRetinaAnimalsGenetic TherapyHumansPlasmidsSwineSwine, Miniature

Identifiers

PMID38457512
PMCPMC10923522
OpenAlexW4392602390

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.